Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note published on Tuesday morning. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.42 on Tuesday. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $6.81. The business’s 50 day simple moving average is $0.68 and its 200 day simple moving average is $2.87.

Hedge Funds Weigh In On Eagle Pharmaceuticals

Several large investors have recently modified their holdings of EGRX. Mackenzie Financial Corp acquired a new stake in Eagle Pharmaceuticals during the 2nd quarter worth approximately $60,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Eagle Pharmaceuticals during the second quarter worth $65,000. Fidelis Capital Partners LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $71,000. Vanguard Personalized Indexing Management LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $76,000. Finally, RBF Capital LLC grew its stake in shares of Eagle Pharmaceuticals by 11.7% in the third quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock valued at $534,000 after acquiring an additional 14,991 shares in the last quarter. 85.36% of the stock is owned by institutional investors.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.